Table 2.
Select studies related to the association of EGFR mutations with the response to cytotoxic chemotherapy in non-small-cell lung cancer
| Author/trial (year) | Number |
EGFR mutation status, n
|
RR
|
PFS (months)
|
OS (months)
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mutation | Wild-type | Mutation | Wild-type | Mutation | Wild-type | Mutation | Wild-type | |||||
| Eberhard et al (2005)55 | 228 | 29 (12.7%) | 199 (87.3%) | 38.0% | 23.0% | TTP | NR | |||||
| P=0.01 | 8.0 | 5.0 | ||||||||||
| P<0.001 | ||||||||||||
| Lee et al (2006)60 | 90 | 17 (18.9%) | 73 (81.1%) | 42.9% | 34.4% | TTP | NR | |||||
| P=0.553 | 7.97 | 6.67 | ||||||||||
| P=0.96 | ||||||||||||
| Hotta et al (2007)56 | 54 | 14 (25.9%) | 40 (74.1%) | 21.4% | 15.0% | 0.422 (0.179–0.991) | 0.263 (0.099–0.699) | |||||
| P=0.6842 | P=0.0422 | P=0.0074 | ||||||||||
| INTEREST (2010)66,67 | 142 | 19 (13.4%) | 123 (86.6%) | 21.1% | 9.8% | NR | 16.6 | 6.0 | ||||
| P=0.59 | ||||||||||||
| Kalikaki et al (2010)57 | 162 | Classical 31 | Wild-type | WT vs classical | TTP | WT vs Classical | ||||||
| Other 9 | 122 (75.3%) | HR 4.85 (1.13–20.83) | 4.4 | 4.1 | HR 2.25 (0.81–6.24) | |||||||
| P=0.034 | P=0.69 | P=0.117 | ||||||||||
| Wu et al (2010)3 | 145 | 55 (37.9%) | 90 (62.1%) | 34.5% | 33.3% | 4.0 | 3.0 | 23.0 | 16.0 | |||
| P=0.881 | P=0.2148 | P=0.0273 | ||||||||||
| HR (0.372–0.961) | 0.598 | |||||||||||
| P=0.0355 | ||||||||||||
| IPASS (2011)51,52 | 214 | 129 (60.3%) | 85 (39.7%) | 47.3% | 23.5% | 6.3 | 5.5 | 21.9 | 12.7 | |||
| Park et al (2012)59 | 217 | 137 (63.1%) | 80 (36.9%) | 33.6% | 35.0% | 4.9 | 4.4 | NR | ||||
| P=0.840 | ||||||||||||
| Dong et al (2013)58 | 229 | 120 (52.4%) | 109 (47.6%) | 35.0% | 34.9% | 9.1 | 8.3 | NR | ||||
| P=0.008 | ||||||||||||
Note: The number ranges given after HR values are 95% confidence interval.
Abbreviations: EGFR, epidermal growth factor receptor; HR, hazard ratio; INTEREST, Iressa NSCLC Trial Evaluating Response and Survival versus Taxotere; IPASS, IRESSA Pan-Asia Study; NR, not reported; OS, overall survival; PFS, progression-free survival; RR, response rate; TTP, time to progression; vs, versus; WT, wild-type.